MRUS - Merus N.V.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
11.70
-0.92 (-7.29%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close12.62
Open12.55
Bid11.65 x 900
Ask13.40 x 1000
Day's Range11.70 - 13.26
52 Week Range11.00 - 26.74
Volume34,389
Avg. Volume44,354
Market Cap265.995M
Beta (3Y Monthly)0.37
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire16 days ago

    Merus Announces IND Clearance for MCLA-145

    “We are pleased to announce the IND authorization to proceed from the FDA and to disclose more details around our latest Biclonics® program today,” said Andres Sirulnik, M.D., Ph. D., Executive Vice President and Chief Medical Officer of Merus. “Our preclinical work has demonstrated that MCLA-145 has the potential to overcome the known side effects of CD137 agonists currently in development and to address a significant unmet need in patient populations not benefitting from current immunotherapeutic agents. Discovered through an unbiased functional screening of multiple immunomodulatory target combinations, MCLA-145 is a Biclonics® T-cell agonist that binds with high affinity and specificity to human PD-L1 and CD137 in preclinical models.

  • CNW Group21 days ago

    ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals

    ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals

  • PR Newswire21 days ago

    ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals

    BERLIN , January 3, 2019 /PRNewswire/ -- Bispecific Antibody for Cancer Treatment Optimized by GlymaxX® Technology ProBioGen AG, a premier service & technology provider for complex therapeutic antibodies ...

  • GlobeNewswire21 days ago

    Merus Announces Strategic Collaboration with Betta Pharmaceuticals to Develop and Commercialize MCLA-129 in China

    Merus to retain all global rights outside of ChinaBetta Pharmaceuticals to fund global IND-enabling activities UTRECHT, the Netherlands, Jan. 02, 2019 -- Merus N.V. (Nasdaq:.

  • GlobeNewswire27 days ago

    Merus Announces Financial Results for the Third Quarter 2018 and Provides Business Update

    Clinical milestones for four lead Biclonics® programs expected in 2019Cash expected to be sufficient to fund operations into the second quarter of 2021 UTRECHT, The.

  • GlobeNewswirelast month

    Merus Announces Global Settlement and End to All Patent Litigation with Regeneron Pharmaceuticals

    Merus N.V. (MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced a settlement of all pending patent litigation and administrative proceedings between Merus and Regeneron Pharmaceuticals, Inc. pertaining to certain antibody generation platforms of each company. As part of the settlement, both parties have signed a global patent cross-license agreement, and Regeneron has agreed to provide an investment in Merus of $15 million through the purchase of 600,000 common shares at a price of $25 per share representing a premium of 118% from the close of trading on December 20, 2018.

  • GlobeNewswire2 months ago

    Merus to Present at the Jefferies 2018 London Healthcare Conference

    UTRECHT, The Netherlands, Nov. 08, 2018 -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics.

  • GlobeNewswire3 months ago

    Report: Developing Opportunities within Spotify Technology SA, Vornado Realty Trust, Merus N.V, Teekay Tankers, PagSeguro Digital, and Liberty Oilfield Services — Future Expectations, Projections Moving into 2018

    NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire6 months ago

    Merus N.V. : Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018

    - Initiation of Phase 1, first-in-human clinical trial of MCLA-158 in patients with solid tumors - - MCLA-128`s unique mechanism of action published in the scientific journal Cancer Cell - UTRECHT, The ...

  • GlobeNewswire7 months ago

    Merus Announces Annual Meeting of Shareholders

    Merus N.V. (MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Annual General Meeting of Shareholders will be held on Friday, July 20, 2018 at 8:00 a.m. CEST, at the offices of NautaDutilh N.V. (address: Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands). All relevant documents and information for the meeting, including the notice and agenda, are available in the `Investor Relations` section of Merus` website (www.merus.nl) under "Financial Information". Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®.

  • GlobeNewswire8 months ago

    Merus to Present at the Jefferies 2018 Healthcare Conference

    UTRECHT, The Netherlands, May 31, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today ...

  • GlobeNewswire8 months ago

    Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors

    Merus N.V. (MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been dosed in a Phase 1, first-in human clinical trial of MCLA-158 in patients with solid tumors with an initial focus on metastatic colorectal cancer. The trial will be conducted in Europe, where several Clinical Trial Applications (CTAs) have been approved to date. The Company also announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MCLA-158, which was accepted by the FDA in April 2018.

  • GlobeNewswire8 months ago

    Merus Announces Unique Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer Cell

    "This study demonstrates the power of empirical functional screening to unlock innovative biology unique to the bispecific antibody format," said Mark Throsby, Ph.D., Executive Vice President and Chief Scientific Officer of Merus. Using unbiased combinatorial screening, we identified a bispecific antibody that employs a unique mechanism to selectively and potently block signaling down this pathway (Dock & Block(TM)). The development candidate advanced from this work, MCLA-128, is being evaluated in multiple clinical studies where this pathway is believed to drive tumor growth and resistance to existing standard of care therapies.